Literature DB >> 23512615

The burden of epiglottitis among Japanese children before the Haemophilus influenzae type b vaccination era: an analysis using a nationwide administrative database.

Masato Takeuchi1, Hideo Yasunaga, Hiromasa Horiguchi, Kiyohide Fushimi.   

Abstract

Epiglottitis is a potentially life-threatening disease and is largely preventable by vaccination against Haemophilus influenzae type b (Hib). Little is known, however, about the epidemiology of childhood epiglottitis in Asian countries, including Japan. Using a nationwide inpatient database, this study aimed to determine the burden of childhood epiglottitis before the introduction of Hib vaccine into Japan. The study period was between July and December in 2007 and 2008, when Hib vaccine was not available. We found 102 cases with epiglottitis among children ≤5 years old. The annual incidence of epiglottitis in children ≤5 years old was estimated to be 3.2 per 100,000 population per year. Among the 102 patients, 31 (30.4%) required respiratory support, including two cases with tracheotomy and one fatal case. Our study demonstrated the substantial burden of epiglottitis among Japanese children, highlighting that a routine Hib vaccination program is essential.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23512615     DOI: 10.1007/s10156-013-0585-x

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  3 in total

Review 1.  A review of factors affecting vaccine preventable disease in Japan.

Authors:  Norimitsu Kuwabara; Michael S L Ching
Journal:  Hawaii J Med Public Health       Date:  2014-12

2.  Otorhinolaryngology litigations in Japan.

Authors:  Toru Hiyama
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-18       Impact factor: 2.503

3.  Cost-effectiveness of the Haemophilus influenzae type b vaccine for infants in mainland China.

Authors:  Guijun Ning; Zundong Yin; Yixing Li; Huaqing Wang; Weizhong Yang
Journal:  Hum Vaccin Immunother       Date:  2017-11-27       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.